Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Persistent microbiome dysbiosis following hematopoietic cell transplantation: Gut GvHD as the most severe manifestation of microbial disruption

Blood (2025) 146 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2025-2465

Published: 2025

Journal Articles

Survival outcomes following second hematopoietic cell transplantation in lymphoma and leukemia: A single-center analysis

Yousef Alghzawi, Bara Hammadeh, Nesreen Alhamwi, Alaa BanyAmer, Mohammad A., Osama Aldeeb, Maryam El-Atrash, Khalid El-Rabii, Husam Abu-Jazar, Khalid Halahleh, Salwa Saadeh, Mohammad Makoseh, Waleed Da'na, Malek AlHourani, Laith Sorour, Rozan Al Far

Blood (2025) 146 (Supplement 1): 7802.

https://doi.org/10.1182/blood-2025-7802

Published: 2025

Journal Articles

GVHD-free/relapse-free survival in severe aplastic anemia: Outcomes following allogeneic hematopoietic cell transplantation: King hussein cancer center experience

Mayada Abu Shanap, Iyad Sultan, Abeer Natsheh, Eman Khattab, Khalid Halahleh, Zaid Abdel Rahman, Mohammad Makoseh, Waleed Da'na, Salwa Saadeh, Rozan Al Far, Husam Abu-Jazar, Rula Najjar, Duaa Zandaki, Rawad Rihani, Hasan Hashem

Blood (2025) 146 (Supplement 1): 2414.

https://doi.org/10.1182/blood-2025-2414

Published: 2025

Journal Articles

Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 3620.

https://doi.org/10.1182/blood-2025-3620

Published: 2025

Journal Articles

GVHD intel 1.0: A scalable, HLA-enhanced machine learning model for predicting acute and chronic GVHD

Naveed Syed, Mohamed Abu Haleeqa, Fatema Al Kaabi, Mohammad Yaqub, Khalid Halahleh, Moussab Damlaj, Mheidly Kayane, Imrana Afrooz, Gehad ElGhazali, Azmat Khan, Farooq Ahmed Mir, Riad Al Hasan, Numan Saeed, Muhammad Ridzuan, Husam Abu-Jazar, Hikmat Abdel Razeq, Mutaz Abu Laila, Shahrukh Hashmi

Blood (2025) 146 (Supplement 1): 4243.

https://doi.org/10.1182/blood-2025-4243

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.

Blood (2025) 146 (Supplement 1): 112.

https://doi.org/10.1182/blood-2025-112

Published: 2025

Journal Articles

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2025-4521

Published: 2025

Journal Articles

Next-generation sequencing-based mutation profile in secondary compared to de novo acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 6069.

https://doi.org/10.1182/blood-2025-6069

Published: 2025

Journal Articles

Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients

Blood (2025) 146 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2025-3192

Published: 2025

Journal Articles

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Blood (2025) 146 (8): 1011–1029.

https://doi.org/10.1182/blood.2024027197

Published: 2025

Includes: Supplemental data

Journal Articles

HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study

Blood (2025) 145 (21): 2518–2527.

https://doi.org/10.1182/blood.2024026915

Published: 2025

Includes: Supplemental data

Journal Articles

Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party

Blood (2024) 144 (Supplement 1): 2184.

https://doi.org/10.1182/blood-2024-208191

Published: 2024

Journal Articles

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 4942.

https://doi.org/10.1182/blood-2024-204672

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4939.

https://doi.org/10.1182/blood-2024-193963

Published: 2024

Journal Articles

Patient Characteristics and Treatment Outcomes of TP53 Mutated Myeloid Neoplasms : A Single Cancer Center Experience from the MENA Region

Kamal Al-Rabi, Mohammad Ma'Koseh, Tamer Al-Batsh, Karim Al Sawalha, Anas Zayed, Abeer Yaseen, Yazan Talab Ahmad, Khalid Halahleh, Waleed Kamel Da'Na, Lina Marei, Farid Barakat, Osama Alsmadi, Zaid Abdel Rahman, Omar Ahmad Shahin, Hikmat Abdel-Razeq

Blood (2024) 144 (Supplement 1): 6717.

https://doi.org/10.1182/blood-2024-209335

Published: 2024

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2024-207545

Published: 2024

Journal Articles

Dose-Adjusted EPOCH-R Is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma

Mohammad Ma'koseh, Abeer Yaseen, Nebras Abu Abed, Omar Ahmad Shahin, Alaa Abufara, Khalid Halahleh, Mohammad Al-Rwashdeh, Zaid Abdel Rahman, Kamal Al-Rabi, Hikmat Abdel-Razeq

Blood (2024) 144 (Supplement 1): 4465.

https://doi.org/10.1182/blood-2024-208323

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Persistent microbiome dysbiosis following hematopoietic cell transplantation: Gut GvHD as the most severe manifestation of microbial disruption

Survival outcomes following second hematopoietic cell transplantation in lymphoma and leukemia: A single-center analysis

GVHD-free/relapse-free survival in severe aplastic anemia: Outcomes following allogeneic hematopoietic cell transplantation: King hussein cancer center experience

Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

GVHD intel 1.0: A scalable, HLA-enhanced machine learning model for predicting acute and chronic GVHD

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Next-generation sequencing-based mutation profile in secondary compared to de novo acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: A study from the ALWP/EBMT

Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study

Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Patient Characteristics and Treatment Outcomes of TP53 Mutated Myeloid Neoplasms : A Single Cancer Center Experience from the MENA Region

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Dose-Adjusted EPOCH-R Is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only